Therapeutic Approach

Archive: June, 2012

Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012

LOS ANGELES, CA – May 22, 2012– Ritter Pharmaceuticals, Inc. presented its abstract summarizing results from its Phase 2 study of RP-G28, a first-in-class treatment for lactose intolerance at the annual international Digestive Disease Week (DDW) 2012®. DDW is considered the largest meeting in the world for physicians and researchers in the fields of gastroenterology, […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD